Navigation Links
A hallmark for the development of testicular tumors found in the aberrant regulation of small non-coding RNA
Date:11/21/2013

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain, have studied the role of a peculiar class of small non-coding RNAs that are mainly expressed in the human male germline. Whereas messenger RNAs transmit the genetic information required for protein synthesis, non-coding RNAs are functional molecules that are never translated into proteins and have important roles in diverse cellular processes. In human spermatozoa, these tiny RNAs are epigenetically regulated (by changes in the genome that do not alter the DNA sequence, such as DNA methylation) and play a critical role in male germline development. Importantly, these RNAs have also been detected in human cancer cells.

In a work published in the January 2014 issue of Epigenetics, which is entirely devoted to "Non-coding RNAs in Epigenetic Regulation," the researchers asked if in their natural functional context (the normal human testis) these small RNAs undergo aberrant epigenetic regulation, compromising their function and contributing to the transformation of cells into testicular tumor cells. The reported data suggest that epigenetic disruption of an entire small non-coding RNA pathway in human testis is indeed a hallmark for the development of testicular tumors.


'/>"/>

Contact: Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience
Source:Eurekalert

Page: 1

Related biology news :

1. Artificial womb unlocks secrets of early embryo development
2. REST is crucial for the timing of brain development
3. Embryonic development protein active in cancer growth
4. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
5. Stomata development in plants unraveled -- a valuable discovery for environmental research
6. Promising developments in early diagnosis and treatment of mesothelioma
7. Europe meets to discuss progress in energy research and development
8. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
9. New genes contributing to autism and related neurodevelopmental disorders uncovered
10. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
11. Navigating the IP Minefield of Human Embryonic Stem Cell Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology: